Preclinical trial of a MAP4K4 inhibitor to reduce infarct size in the pig: does cardioprotection in human stem cell-derived myocytes predict success in large mammals?

Reducing infarct size (IS) by interfering with mechanisms for cardiomyocyte death remains an elusive goal. DMX-5804, a selective inhibitor of the stress-activated kinase MAP4K4, suppresses cell death in mouse myocardial infarction (MI), human pluripotent stem cell-derived cardiomyocytes (hPSC-CMs),...

Descripción completa

Detalles Bibliográficos
Autores principales: te Lintel Hekkert , Maaike, Newton, Gary, Chapman, Kathryn, Aqil, Rehan, Downham, Robert, Yan, Robert, Merkus, Daphne, Whitlock, Gavin, Lane, Charlotte A. L., Cawkill, Darren, Perrior, Trevor, Duncker, Dirk J., Schneider, Michael D.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2021
Materias:
Original Contribution
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8137473/
https://www.ncbi.nlm.nih.gov/pubmed/34018053
http://dx.doi.org/10.1007/s00395-021-00875-7

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8137473/
https://www.ncbi.nlm.nih.gov/pubmed/34018053
http://dx.doi.org/10.1007/s00395-021-00875-7

Ejemplares similares